主要文件

查看所有文档

E1400000

依托红霉素

Name: 依托红霉素
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

Erythromycin 2′-propionate dodecyl sulfate

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:

C₄₀H₇₁NO₁₄ · C₁₂H₂₆SO₄

化学文摘社编号:

3521-62-8

分子量:

1056.39

NACRES:

NA.24

PubChem Substance ID:

329799009

UNSPSC Code:

41116107

MDL number:

MFCD00084691

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

erythromycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCCCOS(O)(=O)=O.CC[C@H]1OC(=O)[C@@H](C)[C@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(O)C[C@H](C)C(=O)C(C)[C@@H](O)[C@@]1(C)O

InChI

1S/C37H67NO13.C12H26O4S/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-12H2,1H3,(H,13,14,15)/t18-,19+,20?,21+,22-,23-,24-,25?,26-,28+,29+,30+,31-,32-,34-,35-,36+,37+;/m0./s1

InChI key

SKDGGFHGLZBNBC-CAHOBLCESA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Erythromycin estolate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 依托红霉素

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H302,H317,H334

pcodes

P261 - P264 - P280 - P301 + P312 - P302 + P352 - P304 + P340 + P312

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Effect of tauroursodeoxycholate on actin filament alteration induced by cholestatic agents. A study in isolated rat hepatocyte couplets.

N Thibault et al.

Journal of hepatology, 19(3), 367-376 (1993-11-01)

The mechanism of the protective effect of ursodeoxycholic acid in cholestatic liver diseases remains unclear. Since there is evidence that alterations in the pericanalicular actin microfilament network play a major role in cholestasis, the aims of this study were (a)

Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections.

S A Halperin et al.

Pediatrics, 100(1), 65-71 (1997-07-01)

Although 14 days of erythromycin is recommended for the treatment of Bordetella pertussis infection, there have been no prospective controlled studies to support the contention that this long course of therapy is required to eradicate the microorganism from the nasopharynx

Use of erythromycin for the treatment of severe chronic constipation in children.

M A Bellomo-Brandão et al.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 36(10), 1391-1396 (2003-09-23)

The efficacy of erythromycin was assessed in the treatment of 14 children aged 4 to 13 years with refractory chronic constipation, and presenting megarectum and fecal impaction. A double-blind, placebo- controlled, crossover study was conducted at the Pediatric Gastroenterology Outpatient

查看所有相关文献

全球贸易项目编号

货号	GTIN
E1400000	04061832574660